Law360, New York (February 22, 2010, 12:56 PM ET) -- Asserting five patents for the antidepressant Aplenzin, Biovail Laboratories International SRL has launched a pair of infringement lawsuits seeking to prevent Watson Pharmaceuticals Inc. from bringing a generic version of the drug to market.
The complaints, filed Thursday in the U.S. District Court for the District of Delaware and Friday in the U.S. District Court for the Southern District of Florida, claim Watson’s recent attempts to gain regulatory approval for generic Aplenzin openly defy the group of unexpired patents covering the depression treatment.
Watson notified Biovail...
Biovail Hammers Watson Over Aplenzin ANDA
To view the full article, take a free trial now.
